ArcSight -- Approac...
Health Care: Drugs
Nabi Pharmaceuticals (NABI: NASDAQ)
$5.06 -0.06 | -1.17%
09/03/10 - 04:00 PM ET
153.95K / 245.90K
Vol / Avg. Vol:5.16 / 5.12
Open / Prev. Close:4.89 - 5.16
Today's Range:3.03 - 6.42
52 Wk Range:3.27%
Performance YTD:TheStreet Rating:
Portfolios with NABI
- Portfolio NameUser Type
- ContributorBarron's Activist Stocks 5-...
- ContributorBarron's Activist Stocks 4-...
- ContributorBarron's Activist Stocks 4-...
- ContributorCharts of the Week - 1-27-2009
- ContributorBarron's Insider Purchases ...
- ContributorBiotech Short Squeezes
- ProThird Point
- ProChapman Capital
- Userwlpncp Portfolio 1
- UserPRossmango - Speculative Lo...
Latest NABI Headlines from TheStreet
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP 09.01.10 | 09:09 am
- Nabi Biopharmaceuticals Significantly Enhances NicVAX Patent Portfolio 08.24.10 | 09:08 am
- Nabi Biopharmaceuticals Completes Third PentaStaph(TM) Milestone 08.10.10 | 09:08 am
- Nabi Biopharmaceuticals Announces Second Quarter 2010 Financial Results 08.05.10 | 04:08 pm
- Nabi Biopharmaceuticals Announces Second Quarter 2010 Financial Results Release Date 07.26.10 | 10:07 am
- Nabi Biopharmaceuticals Completes Enrollment Of First NicVAX Phase III Clinical Trial 07.14.10 | 09:07 am
- Three Investible Ideas: Aeropostale, Nabi, BreitBurn 07.06.10 | 11:07 am
- Nabi Biopharmaceuticals To Present At Noble Financial's Sixth Annual Equity Conference 06.01.10 | 03:06 pm
- Cramer's 'Mad Money' Recap: Preparing for the Selloff (Final) 03.18.10 | 07:03 pm
- 'Mad Money Lightning Round': Keep Raytheon 03.18.10 | 07:03 pm
Press Releases for NABI
Partner Headlines for NABI
- Seth Hamot: Look for Bad Business Models, Too Much Leverage and Selfish Management - Seeking Alpha 07.07.10 | 08:07 am
- Dan Loeb's Hedge Fund Third Point Starts Multiple New Positions, Exits Citigroup - Seeking Alpha 05.24.10 | 05:05 pm
- Nabi Vaccine Program Advances - Analyst Blog - Zacks 03.19.10 | 04:03 pm
